Russell Investments Group Ltd. Raises Stock Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Russell Investments Group Ltd. significantly increased its holdings in Elanco Animal Health by 695.7%, owning 201,389 shares valued at approximately $2.12 million after purchasing an additional 176,078 shares in the first quarter.
• Several other institutional investors, including Allworth Financial LP and Parallel Advisors LLC, also raised their stakes in Elanco Animal Health, contributing to an overall institutional ownership of 97.48% of the company's stock.
• Elanco Animal Health reported $1.24 billion in revenue and earnings per share of $0.26, surpassing analysts' expectations in its most recent quarterly earnings report.

Russell Investments Group Ltd. lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 695.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 201,389 shares of the company's stock after purchasing an additional 176,078 shares during the quarter. Russell Investments Group Ltd.'s holdings in Elanco Animal Health were worth $2,115,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Allworth Financial LP boosted its stake in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after buying an additional 2,090 shares in the last quarter. CoreCap Advisors LLC purchased a new stake in Elanco Animal Health in the fourth quarter worth approximately $29,000. Parallel Advisors LLC boosted its stake in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares in the last quarter. NBC Securities Inc. purchased a new stake in Elanco Animal Health in the first quarter worth approximately $40,000. Finally, Versant Capital Management Inc boosted its stake in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after buying an additional 1,740 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $17.80 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. Elanco Animal Health Incorporated has a fifty-two week low of $8.02 and a fifty-two week high of $18.08. The stock has a 50 day moving average price of $15.16 and a two-hundred day moving average price of $12.52. The company has a market capitalization of $8.84 billion, a P/E ratio of 20.70, a PEG ratio of 3.32 and a beta of 1.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the company posted $0.30 earnings per share. The business's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ELAN. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Piper Sandler upped their target price on Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Stifel Nicolaus upped their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Leerink Partners raised Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price for the company in a research note on Thursday, July 17th. Finally, Zacks Research downgraded Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.